Cabostar: A phase II, randomised, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment
ChonDRAgon: A randomised, blinded, placebo-controlled, phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma
CHONQUER: A phase 3, multicentre, double blind, randomised, placebo-controlled study of ivosidenib in participants ≥ 18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen
EORTC QOL: Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients
FaR-RMS: An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma
ICONIC: Improving outcomes through collaboration in osteosarcoma
Inter-Ewings: International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma - Trial 1 (INTER-EWING-1)
KINDRED ASSG: The International Sarcoma Kindred study: A global multi-site prospective cancer genetics study
PH1 Inhibrix: An open-label, multicentre, first-in-human, phase 1 dose escalation and multicohort expansion study of INBRX-109 in subjects with locally advanced or metastatic solid tumours, including sarcomas
Pharma Mar: Randomised, controlled, open-label, phase IIb/III study of Lurbinectedin in combination with Doxorubicin vs. Doxorubicin alone as a first-line treatment in patients with metastatic leiomyosarcoma.
PREDICT B: Predicting radiotherapy response, toxicities and quality of life related functional outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study
rEECUr: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Tangent (SNX-301-020): A phase III, multicentre, randomised, double-blind study to assess the safety and efficacy of Emactuzumab vs. placebo in subjects with Tenosynovial Giant Cell Tumour
** Sometimes there may be other trials open - it is always worth asking your doctor. **
